# ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors

> **NCT04732065** · PHASE1 · RECRUITING · sponsor: **Sabine Mueller, MD, PhD** · enrollment: 208 (estimated)

## Conditions studied

- Diffuse Midline Glioma (DMG)
- Glioblastoma
- Recurrent Ependymoma
- Recurrent Malignant Central Nervous System Neoplasm
- Spinal Cord Glioma
- World Health Organization (WHO) Grade III Glioma
- CNS Tumor
- Central Nervous System Tumor

## Interventions

- **DRUG:** ONC206
- **RADIATION:** Standard of Care Radiation Therapy
- **PROCEDURE:** Optional Proton (1H) MR spectroscopy (MRS)

## Key facts

- **NCT ID:** NCT04732065
- **Lead sponsor:** Sabine Mueller, MD, PhD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-08-23
- **Primary completion:** 2027-05-31
- **Final completion:** 2027-07-31
- **Target enrollment:** 208 (ESTIMATED)
- **Last updated:** 2026-03-17

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04732065

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04732065, "ONC206 for Treatment of Newly Diagnosed, Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant CNS Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04732065. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*